Verastem, Inc.
VSTM · NASDAQ
Market closed$6.03$0.260000 (+4.51%)After hours $5.95 · -1.33%
Key statistics
Previous close$5.77
Open$5.76
Day high$6.07
Day low$5.56
52-week high$11.25
52-week low$3.43
Market cap417.96M
Volume3.56M
Average volume2.62M
P/E ratio-2.33
Forward P/E—
EPS-2.59
Dividend yield0.00%
Market context
Why it moved
Verastem's VSTM stock rose today after the company announced that its KRAS G12D clinical trial targeting colorectal cancer is actively recruiting patients, reinforcing a compelling pipeline narrative in a high-interest area of oncology and boosting investor sentiment.
What is happening
Recent company-specific developments and publisher coverage.
Investing.com · June 24, 2026H.C. Wainwright reiterates Verastem stock rating on drug trial dataInvesting.com · June 23, 2026Verastem stock falls despite early cancer drug trial dataStock Titan · June 23, 2026Verastem says VS-7375 hit pancreatic, colon and lung tumorsSeeking Alpha · June 17, 2026Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program (VSTM)Clinical Trials Arena · June 17, 2026Verastem Oncology’s pancreatic cancer combo shows 86% OS rateBusiness Wire · June 15, 2026Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical ProgramSimply Wall Street · May 11, 2026Analysts Are Updating Their Verastem, Inc. (NASDAQ:VSTM) Estimates After Its First-Quarter ResultsBusiness Wire · May 7, 2026Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates Benzinga · July 7, 2026RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14 Mt Newswire · July 7, 2026RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating Mt Newswire · June 24, 2026Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says Benzinga · June 24, 2026BTIG Reiterates Buy on Verastem, Maintains $18 Price Target Mt Newswire · June 23, 2026Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors Benzinga · June 17, 2026Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer Mt Newswire · June 16, 2026Verastem Doses First Patient in Phase 2 Trial of VS-7375 for Pancreatic Cancer Benzinga · June 16, 2026Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma